Guildford, UK, March 26, 2018
-- MedPharm Ltd., a leading provider of contract topical and transdermal product design and formulation development services, is pleased to announce an investment by Ampersand Capital Partners.
Since its founding almost 20 years ago, MedPharm has established itself as a trusted developer of topical and transdermal products for the pharmaceutical drug development communities worldwide. The Company’s services currently encompass formulation development, performance testing and clinical trials manufacturing at its facilities in Guildford, UK and Durham, NC, US.
MedPharm’s founders, Dr. Andrew Muddle and Prof. Marc Brown, will remain with the Company to work with its growing executive team to expand MedPharm’s service offering in topical and transdermal pharmaceutical development and manufacturing, as well as increase international CDMO market coverage whilst maintaining the Company’s long established scientific principles and ethos.
Dr. Andrew Muddle, co-Founder and CEO of MedPharm, stated, “We are excited to partner with Ampersand to diversify MedPharm’s services offering and regional coverage. We look forward to growing the business together for the benefit of our customers.”
Professor Marc Brown, Founder and CSO of MedPharm, commented, “We have chosen to partner with Ampersand at an opportune time. Ampersand’s investment will help us respond to strong market demand for MedPharm’s services whilst maintaining our core values of scientific integrity, innovation and flexibility.”
Ampersand General Partner David Parker added, “MedPharm is an excellent fit with Ampersand’s strategy of investing in growth-oriented businesses that have established leadership positions in specialty segments of the CDMO market. We are thrilled to have the opportunity to partner with MedPharm’s management team to drive future growth and success of the business.”
MedPharm Ltd. is a leading, global provider of contract topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through proprietary, industry-leading performance testing models. Well-established as a global leader in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm also offers innovative solutions for ophthalmic and airway preparations. These solutions are recognized for their scientific rigor by regulators and investors. MedPharm has fully established R&D centres in the U.S. and U.K. and GMP clinical manufacturing at its global headquarters facility in Guildford, UK. For more information visit the new website www.medpharm.com
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics and Viracor-IBT Laboratories. Additional information about Ampersand is available at www.ampersandcapital.com